$5.840
0.000 (0.00%)Al cierre
Noticias de NVRO
Eventos de NVRO
Thirteen option delistings on April 22nd
Option delistings effective April 22nd include PAYCOR HCM INC. (PYCR), PACTIV EVERGREEN INC. (PTVE), Nevro Corp (NVRO), American Software, Inc. (LGTY), Intevac, Inc. (IVAC), Intra-Cellular Therapies Inc (ITCI), Gritstone Bio, Inc. (GRTSQ), Enfusion (ENFN), ENDEAVOR GROUP HOLDINGS INC. (EDR), Air Transport Services Group Inc. (ATSG), Altair Engineering Inc (ALTR), ACCOLADE INC (ACCD), and VOXX International Corp (VOXX).
Globus Medical completes acquisition of Nevro
Globus Medical (GMED) announced the completion of its previously disclosed acquisition of Nevro (NVRO). The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal market, unlocking a $2.5B market opportunity. This strategic move positions Globus to further add to its product portfolio with the potential to alter the standard of care in the neuromodulation space and beyond. Globus Medical plans to discuss the closing of the acquisition and the anticipated benefits of the expanded product offering during its first quarter earnings conference in May.
Nevro is not issuing FY25 guidance
As previously announced on February 6, given the pending acquisition of Nevro by Globus Medical, Nevro is not issuing FY25 guidance, nor is the company holding an earnings conference call and webcast in connection with reporting its Q4 and FY24 financial results.
Nevro reports Q4 EPS ($1.41), consensus (75c)
Reports Q4 revenue $105.5M, consensus $102.61M. Cash, cash equivalents and short-term investments totaled $292.5M as of December 31, 2024, an increase of $15.5M from September 30, 2024. "We are pleased that adjusted EBITDA for the FY24 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free patients from the burden of chronic pain."
Globus acquisition of Nevro 'fairly low-risk bet,' says BTIG
BTIG says Globus Medical's (GMED) announced acquisition of Nevro (NVRO) "is surprising on the surface." Investors did not expect Globus would move into neuromodulation or pain stim as a market adjacency, especially as it digested its largest acquisition to date with NuVasive, the analyst tells investors in a research note. That said, Globus is buying Nevro for a very low amount of cash and the deal is "fairly low-risk bet," contends BTIG. The firm believes Globus gains access to a few assets that are more complimentary than neuromodulation, and it also thinks that if the company can use Nevro's pain stimulation channel to sell additional imaging technology, it will increase the value of Globus'; enabling technology ecosystem over time. Nevro could add $35M-$40M in operating profit in fiscal 2026, BTIG estimates. It keeps a Buy rating on Globus Medical with a $91 price target.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.